Companion diagnostics join hands with innovative drugs to open an era of precise tumor treatment

"If innovative drugs play an important role in tumor treatment, in this process, companion diagnostic products, like innovative drugs, must be a rigid demand for patients

Recently, Aide Bio announced that it has reached a global companion diagnostic cooperation with AstraZeneca, an innovative tumor pharmaceutical company, and the cooperation market has expanded from China to global markets such as Japan and the European Union

"Previously, for most tumor patients, the traditional treatment methods were mainly chemotherapy and radiotherapy, which have serious side effects, but now, we have gradually entered the era of targeted drugs and immunotherapy, and tumor treatment methods have begun to This change has also brought tumor treatment into the era of precision medicine

Dr.

It is against this background that companion diagnostics came into being

Companion diagnostics have become a rigid need for precise tumor treatment

Dr.

"Companion diagnosis has many application scenarios.

Recently, Aide Bio and AstraZeneca, an innovative tumor pharmaceutical company, have reached a global companion diagnostic cooperation, and the cooperation market has expanded from China to global markets such as Japan and the European Union

Aide Bio has long insisted on using 15%-20% of its operating income for research and development, and has formed independent intellectual property rights in technologies such as ADx-ARMS, Super-ARMS, PCR Panel, ADx-HANDLE, etc.

"Enable domestic tumor patients to receive compliant and high-quality diagnosis, which is the original intention of Aide that has been rooted in the industry for 14 years

Talking about the future layout, Dr.